DSS1 and p53 are required for homologous recombination, but, although p53 inactivation has a key function in skin tumorigenesis, there is no clear evidence supporting a function of DSS1. We screened the entire DSS1 coding sequence and p53 exons 5–8 in a series of 60 cases of skin squamous cell carcinoma (SCC). Mutational analysis of p53 revealed tumor-associated mutations in 28 (46.7%) of the cases. No tumor-associated DSS1 mutations were detected; however, the germline DSS1 c.143G4A synonymous polymorphism had a significantly higher frequency in patients with SCC (16.67%) versus healthy subjects (5%). DSS1 expression was evaluated by quantitative real-time RT-PCR and immunohistochemistry. With respect to c.143G4G genotype, SCCs and adjacent normal tissues carrying the c.143G4A polymorphism showed significantly lower DSS1 RNA and protein levels and a prevalent cytoplasmic rather than nuclear localization of DSS1 protein. The assay for mRNA stability revealed that the c.143G4A polymorphism affects DSS1 expression efficiency, but not mRNA decay. We clearly showed that the c.143G4A variant is associated with reduced DSS1 expression at both the RNA and protein levels and with altered traffic of the DSS1 protein from the cytoplasm to the nucleus. These alterations could impair DSS1 function in DNA repair and may be implicated in skin cancer.
Association of DSS1 c.143G>A polymorphism with skin squamous cell carcinoma.
CURIA, Maria Cristina;MARIANI COSTANTINI, Renato;
2010-01-01
Abstract
DSS1 and p53 are required for homologous recombination, but, although p53 inactivation has a key function in skin tumorigenesis, there is no clear evidence supporting a function of DSS1. We screened the entire DSS1 coding sequence and p53 exons 5–8 in a series of 60 cases of skin squamous cell carcinoma (SCC). Mutational analysis of p53 revealed tumor-associated mutations in 28 (46.7%) of the cases. No tumor-associated DSS1 mutations were detected; however, the germline DSS1 c.143G4A synonymous polymorphism had a significantly higher frequency in patients with SCC (16.67%) versus healthy subjects (5%). DSS1 expression was evaluated by quantitative real-time RT-PCR and immunohistochemistry. With respect to c.143G4G genotype, SCCs and adjacent normal tissues carrying the c.143G4A polymorphism showed significantly lower DSS1 RNA and protein levels and a prevalent cytoplasmic rather than nuclear localization of DSS1 protein. The assay for mRNA stability revealed that the c.143G4A polymorphism affects DSS1 expression efficiency, but not mRNA decay. We clearly showed that the c.143G4A variant is associated with reduced DSS1 expression at both the RNA and protein levels and with altered traffic of the DSS1 protein from the cytoplasm to the nucleus. These alterations could impair DSS1 function in DNA repair and may be implicated in skin cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.